Evidence map›Paper›PMID 31106680›Full record

ArticleTechnology in cancer research & treatment2019

LncRNA-SRA1 Suppresses Osteosarcoma Cell Proliferation While Promoting Cell Apoptosis.

Wen Guo, Haitao Jiang, Haijun Li, Fang Li, Qing Yu, Yu Liu, Weiwei Jiang, Ming Zhang

Open access · goldAbstract read
In one paragraph

Article in Technology in cancer research & treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Long noncoding RNAAging · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Wen Guo1 Department of Orthopedics, Taizhou People's Hospital, Taizhou, Jiangsu, China.
Haitao Jiang1 Department of Orthopedics, Taizhou People's Hospital, Taizhou, Jiangsu, China.
Haijun Li1 Department of Orthopedics, Taizhou People's Hospital, Taizhou, Jiangsu, China.
Fang Li2 Department of Neurology, Taizhou Hospital of Traditional Chinese Medicine, Taizhou, Jiangsu, China.
Qing Yu1 Department of Orthopedics, Taizhou People's Hospital, Taizhou, Jiangsu, China.
Yu Liu1 Department of Orthopedics, Taizhou People's Hospital, Taizhou, Jiangsu, China.
Weiwei Jiang1 Department of Orthopedics, Taizhou People's Hospital, Taizhou, Jiangsu, China.
Ming Zhang1 Department of Orthopedics, Taizhou People's Hospital, Taizhou, Jiangsu, China.ORCID 0000-0002-2774-7839
Nantong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveOsteosarcoma is a common malignant bone tumor that is frequently found in the long bones of children and adolescents. The aim of this study is to examine long noncoding RNA-steroid receptor RNA activator 1 expression in osteosarcoma to explore the biological function of long noncoding RNA steroid receptor RNA activator 1 on proliferation, migration, and invasion along with apoptosis and its regulatory mechanism, which would facilitate the early diagnosis and targeted therapy of osteosarcoma.

methodsFirst, microarray analysis was applied to determine the expression of long noncoding RNAs in osteosarcoma tissues and paired normal tissues. Then, quantitative real-time polymerase chain reaction was utilized to validate microarray findings. Next, osteosarcoma cancerous cell lines SJSA-1 and U2OS were transfected with pcDNA3.1-SRA1 or pCMV-sh-SRA1 to increase or decrease steroid receptor RNA activator 1 expression levels, and microRNA-208a inhibitors, mimic to investigate the effects of microRNA-208a on osteosarcoma as well as the regulatory relation between long noncoding RNA steroid receptor RNA activator 1 and microRNA-208a. Cell proliferation was evaluated through Cell Counting Kit-8 and colony formation assays. Flow cytometry analysis was conducted to evaluate the apoptosis ratio. The migration and invasion abilities were measured using wound-healing and transwell assays.

resultsLong noncoding RNA-steroid receptor RNA activator 1 expression was downregulated in osteosarcoma tissues and cells compared with that in corresponding normal tissues, whereas microRNA-208a expression was upregulated in osteosarcoma tissues. Moreover, the restoration of long noncoding RNA steroid receptor RNA activator 1 inhibited cell proliferation, and upregulation of long noncoding RNA steroid receptor RNA activator 1 restrained cell migration and invasion but boosted the apoptosis rate in osteosarcoma cells. In addition, long noncoding RNA steroid receptor RNA activator 1 targeting microRNA-208a was involved in the progression of osteosarcoma. Furthermore, upregulating microRNA-208a exerted similar roles of silencing long noncoding RNA steroid receptor RNA activator 1 in cell apoptosis, proliferation, migration, and invasion, which were reversed by enhancing the expression of long noncoding RNA steroid receptor RNA activator 1.

conclusionsIn our study, long noncoding RNA steroid receptor RNA activator 1 played an antitumor role in osteosarcoma as it reduced cell migration, invasion, and proliferation, but facilitated cell apoptosis via sponging microRNA-208a, which could be regarded as a potential therapeutic target of osteosarcoma treatment.

Indexed as

ApoptosisBone NeoplasmsCarrier ProteinsCell Line, TumorCell MovementCell ProliferationComputational BiologyGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMicroRNAsOsteosarcomaRNA InterferenceRNA, Long NoncodingCarrier ProteinsMicroRNAsMIRN208 microRNA, humanRNA, Long Noncodingsteroid receptor RNA activator, humancell multiplicationlong noncoding RNAosteogenic sarcomaprogrammed cell deathsteroid receptor RNA activator 1

Identifiers

PMID31106680
PMCPMC6535715
OpenAlexW2944841657

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.